apocell Home Contact Us
  • OVER 175 CLINICAL TRIALS TO DATE


  • contact us
  • News

Cells speak. We translate.

The key to ApoCell’s leadership in biomarker research is our ability to use cutting edge techniques for the quantitative analysis of rare circulating cells. ApoCell’s technologies allow for the study of cells at the level of single rare cells (CTCs, CEC, stem cells) to provide clients with qualitative and quantitative morphologic observations, protein and mRNA expression analysis, and analysis of genetic alterations. Platform technologies are integrated to characterize rare cells in a progressive, step-wise manner for protein expression, apoptosis, molecular profiling, and finally genetic mutations. Profiling of rare cells can greatly facilitate patient stratification to enhance success in clinical trials.

integrated platforms